Their presence is of major clinical interest because of the poor prognosis and limited therapeutic options in this rare disease, so that eight patients with ALK+ LCNEC have been published so far, which are summarized in Table 3. The gene discussed is ALK; the disease is large cell neuroendocrine carcinoma.